Research

2017 in Review: The Most-Read FFB Stories of 2017

December 22nd, 2017 by FFB Canada

At the FFB, we love writing about vision research. In 2017, we wrote more than 50 stories to share news about stem cell discoveries, CRISPR gene-editing, promising new drug therapies, and emerging treatments for blinding eye disease. Have you read them all? The best place to start is with our top 10 most-read stories of…

Read More

First gene therapy for a blinding eye disease receives FDA approval

December 19th, 2017 by Dr. Mary Sunderland

Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the US that targets a disease caused by mutations in a specific gene. The next steps involve determining the price for Luxturna, which poses…

Read More

Survival of the Fittest: Sustaining Cells Through Transplantation

December 18th, 2017 by Dr. Chad Andrews

In many retinal diseases, vision loss occurs when cells that are crucial for vision are damaged or lost. This is the case, for example, in age-related macular degeneration (AMD), retinitis pigmentosa, choroideremia, and Stargardt disease. To reverse vision loss resulting from these and similar diseases, we need to develop and refine our ability to replace…

Read More

Understanding the Retina: AMD and Exploratory Science

December 1st, 2017 by Dr. Chad Andrews

In medicine, innovative treatments don’t emerge out of thin air; they are the result of a series of advancements in our understanding of how genes, molecules, and cells interact. The human eye is no stranger to this rule. In fact, there is still much we don’t understand about the genetic and cellular foundations of sight….

Read More

The Value of iPSCs for Stem Cell Therapy

November 22nd, 2017 by Dr. Chad Andrews

Stem cell therapy has emerged as one of the most promising approaches in the fight to end blindness, and Dr. Gilbert Bernier’s research has played an enormous role in pushing the field forward. By developing new techniques to turn induced pluripotent stem cells (iPSCs) into sheets of cone photoreceptors, Dr. Bernier and his team are…

Read More

New Gene That Could Cure Blindness [Facebook Live] (Video)

November 10th, 2017 by FFB Canada

Watch our Facebook Live Session from November 10, 2017, where the FFB’s Research and Education Team, Dr. Mary Sunderland and Dr. Chad Andrews, discussed a new gene that could cure blindness and our top learnings from Vision Quest. CLICK HERE to view more Facebook Live videos. MAKE A DONATION TODAY

Top 10 Things We Learned at Vision Quest 2017

November 7th, 2017 by Dr. Mary Sunderland

Vision Quest is the FFB’s educational program series that brings trusted information about emerging sight-saving treatments to people living with vision loss. This year, Vision Quest brought together more than 860 people at 9 different events across Canada. The entire FFB staff participates in Vision Quest because it gives us the opportunity to learn directly…

Read More

Clinician-Scientist Emerging Leader Award: Dr. Brian Ballios

November 1st, 2017 by FFB Canada

Dr. Brian Ballios has restored vision in mice, but he is not stopping there. He is on a mission to develop stem cell therapies for people living with blindness and has a plan to get there. Dr. Ballios and other clinician-scientists are essential players in the translation of pre-clinical vision research into clinical trials and…

Read More

New Master Control Gene Provides Key Insights into Restoring Vision

October 31st, 2017 by Dr. Chad Andrews

With support from the FFB community, Dr. Michel Cayouette’s research is advancing the field of stem cell therapy in extraordinary ways; it is doing so by illuminating how stem cells are produced, how they turn into other cells, and the role they play in the overall biology of the human eye. Dr. Cayouette’s ultimate goal?…

Read More

FDA Panel Votes Unanimously to Approve New Gene Therapy

October 13th, 2017 by Dr. Mary Sunderland

History was made on World Sight Day, October 12, 2017, when an FDA advisory panel voted unanimously to approve a new gene therapy, Luxturna, designed to treat inherited blinding eye diseases caused by mutations in the RPE65 gene. We have been following this story closely over the past few years and celebrating every milestone along…

Read More